Mr. Shaun Flanagan:

The Orkambi deal is a complicated one which involves a portfolio and what drug prices will be in future with further lines. It is very difficult to describe it in simple cost terms. Our understanding is that the Australian Government took the exact same deal as we negotiated first and we understand the UK's NHS is engaged currently in a similar portfolio deal. The cost per patient of Orkambi is approximately €12,000 per month.